Nomic Bio partnered with Broad Clinical Labs to embed its Nomic Omni 1000 immunoassay platform into BCL’s proteomics and multi-omics offerings. The collaboration is designed to connect large-scale proteomic quantification with genomic risk modeling and precision oncology workflows, including applications in biomarker development and clinical trials. Nomic said its Omni 1000 uses bead-based nELISA technology to multiplex hundreds to thousands of immunoassays quickly with absolute quantification and without antibody cross-reactivity, positioning it as a scalable proteomics layer. BCL expects to begin offering jointly developed applications in early 2027, with initial integration work already underway. Terms were not disclosed.